Join collection
Hello, welcome to our official website!
2018全球智能工业大会亮点前瞻
2019-01-12

  - 你想要知道的关于智能工业的一切,尽在2018全球智能工业大会

  

  北京2018年5月15日电 /美通社/ -- 由中国工程院、中央军委科学技术委员会共同主办,中国工程院信息与电子工程学部、中国光学工程学会、北京经济技术开发区管理委员会共同承办的2018全球智能工业大会暨全球创新技术成果转移大会暨博览会,将于2018年5月22-24日在北京亦创国际会展中心盛大开幕。活动由全球智能工业大会、智能工业大会主题论坛、国际创新合作论坛、平行交流会及博览会等五大部分组成,全方位、多层次、多角度打造智能工业全球盛宴。

  

  一、全球智能工业大会:**创新产业变革,开创中国智能新未来

  

  全球智能工业大会在开幕式之后,将依次举办国际智能工业高端论坛及智能工业创新设计高峰论坛。

  

  1、国际智能工业高端论坛:高端大会报告带你大格局看待智能工业

  

  德国弗劳恩霍夫激光研究所所长 Prof. Dr. Reinhart Poprawe 教授将作报告《Digital Photonic Production along the lines of Industry 4.0》,英国原子能机构 Rob Buckingham 博士将作报告《Robots in extreme environments》,澳大利亚乐卓博大学 John Dewar 博士将作报告《Higher Education and Technological Convergence - University 4.0》,中国清华大学尤政院士将作报告《NS-2: demonstrating a flexible nano-spacecraft platform and self-developed MEMS devices》,韩氏激光智能设备集团有限公司冯建国博士将作报告《Innovation Practice of smartmanufacturing in Han's Laser Smart Equipment》。

  

  2、智能工业创新设计高峰论坛:热门企业报告与你**率把握行业动态

  

  北京全路通信信号研究设计院集团周炜总经理将作报告《浅谈中国轨道交通工业智能化》,小米人工智能与云平台崔宝秋副总裁将作报告《小米的AI之路》,IBM电子行业全球工业4.0及智能制造邓钦将作报告《创新技术点燃“智”造之光》,通鼎互联信息股份有限公司蔡文杰总裁将作报告《通鼎互联智能制造新模式》,新南威尔士大学Warwick Dawson将作报告《Torch Innovation Precinct at UNSW》,中国联通盛煜将作报告《低空通信网助力无人机产业健康发展》。

  

  二、智能工业大会主题论坛:广阔的细分行业市场,在这里汇聚

  

  包含人工智能高峰论坛、工业机器人与智能控制高峰论坛、自动驾驶前沿技术及产业发展高峰论坛、智能检测与装配系统解决方案高峰论坛、智能工控与安全防护高峰论坛、智能硬件产业发展高峰论坛、中国无人机产业创新联盟成立大会暨智能无人系统大会、智能无人系统大会-反无人飞行器技术及城市安防论坛、智能无人系统大会-智能无人系统控制论坛、中国无人机产业创新联盟自然资源与测绘分联盟第一次工作会、以及2018国际激光智造高峰论坛暨国际激光技术产业及应用协同创新联盟成立大会。

  

  三、国际创新合作论坛:国际项目团队和需求团队与国内的深入对接

  

  分为亚欧科技创新合作发展论坛、“一带一路”国际合作对接会、欧洲国际项目推介专场、中澳创新技术论坛(新南威尔士大学专场)、中意智能制造专场、技术创新与投融资合作对接专场、以及第二届中澳先进制造技术专场。

  

  四、平行交流会:交叉领域学会的研讨盛会

  

  包罗新型激光器技术与应用研讨会、三维图像获取与显示技术及应用研讨会、光电探测成像技术与应用研讨会、光学超精密加工与检测技术及应用研讨会、微光学与微光机电技术与应用研讨会、2018年中国(北京)海洋信息网络技术及产业发展大会、2018第七届红外与光电子产业发展论坛暨红外微光技术应用产业联盟年会、关键光器件在光纤传感中的应用研讨会(企业专场)、光纤传感在矿山安全中的应用研讨会、云时代的光通信转型 -- 第二届光信息与光网络大会、第七届中国(北京)国际光纤传感技术及应用大会主论坛、光纤传感在土木工程基础设施中的应用研讨会、光纤传感技术在智能电网中的应用、光纤传感在轨道交通中的应用研讨会。

  

  五、博览会:为智能工业产业链上下游的先进产品与研究成果提供展示舞台

  

  博览会囊括2018全球智能工业博览会、2018年中国(北京)国际高新技术交流展洽会暨第十届光电子中国博览会以及第三届中国(北京)无人机产业博览会。

  

  分设全球高校、研究所、重点实验室创新技术主题展,激光智能制造主题展,军民两用红外微光技术及应用主题展,智能信息主题展,光学制造主题展,军民融合国防电子主题展,无人机主题展七大展区,总展出面积超过30000平方米,有来自国内外700余家高校及企业参展,预计10万人次专业买家和观众到场参观采购。

  

  展区汇聚智能工业龙头企业及科研机构:江苏亨通光电股份有限公司、湖北久之洋红外系统股份有限公司、福建福光股份有限公司、浙江大立科技股份有限公司、中国航空工业集团公司洛阳电光设备研究所、广州飒特红外股份有限公司、北京微纳光科仪器有限公司、深圳市镭神智能系统有限公司、昂纳信息技术(深圳)有限公司、武汉中科锐择光电科技有限公司、山东海富光子科技股份有限公司、东莞鼎企智能自动化科技有限公司、长春博信光电子有限公司;澳大利亚中国先进材料与制造协会、中国航天科工集团公司、光启集团、北京航天计量测试技术研究所、石家庄高新技术产业开发区、深圳市大疆创新科技有限公司、山东龙翼航空科技有限公司、深圳一电科技有限公司、青岛欧森系统技术有限公司等知名单位都将携带新品悉数到场。


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online